MX2015008978A - Formas de sal de meglumina del acido 2-( (1r, 4r)-4-(4-(5- (benzoxazol-2-ilamino) piridin-2-il) fenil) ciclohexil)-acetico, y su uso como inhibidores de acil-coa-diacilglicerol-acil-transfer asa 1 (dgat1). - Google Patents

Formas de sal de meglumina del acido 2-( (1r, 4r)-4-(4-(5- (benzoxazol-2-ilamino) piridin-2-il) fenil) ciclohexil)-acetico, y su uso como inhibidores de acil-coa-diacilglicerol-acil-transfer asa 1 (dgat1).

Info

Publication number
MX2015008978A
MX2015008978A MX2015008978A MX2015008978A MX2015008978A MX 2015008978 A MX2015008978 A MX 2015008978A MX 2015008978 A MX2015008978 A MX 2015008978A MX 2015008978 A MX2015008978 A MX 2015008978A MX 2015008978 A MX2015008978 A MX 2015008978A
Authority
MX
Mexico
Prior art keywords
ylamino
pyridin
cyclohexyl
phenyl
acetic acid
Prior art date
Application number
MX2015008978A
Other languages
English (en)
Inventor
Christina Capacci-Daniel
Marilyn Delacruz
Baoqing Gong
Akash Jain
Yansong Lu
Lijun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015008978A publication Critical patent/MX2015008978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a formas cristalinas novedosas de ácido 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ilamino)piridin-2-il )fenil)- ciclohexil)acético de la fórmula (I) y su uso en el tratamiento o prevención de una afección o trastorno asociado con la actividad de DGAT1 en los animales, particularmente los humanos.
MX2015008978A 2013-01-11 2014-01-10 Formas de sal de meglumina del acido 2-( (1r, 4r)-4-(4-(5- (benzoxazol-2-ilamino) piridin-2-il) fenil) ciclohexil)-acetico, y su uso como inhibidores de acil-coa-diacilglicerol-acil-transfer asa 1 (dgat1). MX2015008978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751443P 2013-01-11 2013-01-11
PCT/US2014/011005 WO2014110344A1 (en) 2013-01-11 2014-01-10 Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors

Publications (1)

Publication Number Publication Date
MX2015008978A true MX2015008978A (es) 2015-09-29

Family

ID=50001335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008978A MX2015008978A (es) 2013-01-11 2014-01-10 Formas de sal de meglumina del acido 2-( (1r, 4r)-4-(4-(5- (benzoxazol-2-ilamino) piridin-2-il) fenil) ciclohexil)-acetico, y su uso como inhibidores de acil-coa-diacilglicerol-acil-transfer asa 1 (dgat1).

Country Status (16)

Country Link
US (2) US8987459B2 (es)
EP (1) EP2943488B1 (es)
JP (1) JP6302937B2 (es)
KR (1) KR20150103747A (es)
CN (1) CN104995188B (es)
AR (1) AR101523A1 (es)
AU (1) AU2014205276B2 (es)
BR (1) BR112015016370A2 (es)
CA (1) CA2896861A1 (es)
EA (1) EA027688B1 (es)
ES (1) ES2675398T3 (es)
MX (1) MX2015008978A (es)
PL (1) PL2943488T3 (es)
PT (1) PT2943488T (es)
TR (1) TR201808198T4 (es)
WO (1) WO2014110344A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2943488T (pt) * 2013-01-11 2018-06-12 Novartis Ag Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
BR112020021153A2 (pt) * 2018-04-17 2021-03-23 Cardurion Pharmaceuticals, Llc sais de meglumina de tienopirimidinas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP2004607B1 (en) * 2006-03-31 2011-10-19 Novartis AG (4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-N-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
PT2943488T (pt) * 2013-01-11 2018-06-12 Novartis Ag Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1

Also Published As

Publication number Publication date
EA201591300A1 (ru) 2015-11-30
JP6302937B2 (ja) 2018-03-28
CN104995188A (zh) 2015-10-21
US20140200246A1 (en) 2014-07-17
US9242971B2 (en) 2016-01-26
AR101523A1 (es) 2016-12-28
ES2675398T3 (es) 2018-07-11
AU2014205276A1 (en) 2015-07-16
US20150166522A1 (en) 2015-06-18
PT2943488T (pt) 2018-06-12
PL2943488T3 (pl) 2018-09-28
BR112015016370A2 (pt) 2017-07-11
WO2014110344A1 (en) 2014-07-17
KR20150103747A (ko) 2015-09-11
AU2014205276B2 (en) 2016-10-20
JP2016505017A (ja) 2016-02-18
EP2943488A1 (en) 2015-11-18
US8987459B2 (en) 2015-03-24
CN104995188B (zh) 2018-09-14
EP2943488B1 (en) 2018-03-28
CA2896861A1 (en) 2014-07-17
TR201808198T4 (tr) 2018-07-23
EA027688B1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
NZ627586A (en) Pyridone derivatives
HK1217487A1 (zh) 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
EA201201648A1 (ru) Стимуляторы sgc
WO2014144100A3 (en) Sgc stimulators
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
UA109547C2 (uk) Композиція для боротьби з захворюванням рослин і спосіб боротьби з захворюванням рослин
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201491936A1 (ru) Азотсодержащее гетероциклическое соединение
PH12015500678A1 (en) Crystalline forms of a factor xia inhibitor
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
HK1214822A1 (zh) 新型 苄氧基 苯基 己- -炔酸衍生物、其製備方法、和包括其作為有效成分的用於預防和治療代謝性疾病的藥物組合物
MX336346B (es) Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
IN2014CN04204A (es)
EA201390457A1 (ru) Полиморфы и соли 6-(1h-индол-4-ил)-4-(5-{[4-(1-метилэтил)-1-пиперазинил]метил}-1,3-оксазол-2-ил)-1h-индазола в качестве ингибиторов pi3k для применения в лечении, например, респираторных расстройств
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
NZ621155A (en) Plant disease control composition and its use
GT201300089A (es) Nuevas formas cristalinas de la sal sodica del acido (4-(4-(5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il)-fenil)-ciclohexil)-acetico
MX2015008978A (es) Formas de sal de meglumina del acido 2-( (1r, 4r)-4-(4-(5- (benzoxazol-2-ilamino) piridin-2-il) fenil) ciclohexil)-acetico, y su uso como inhibidores de acil-coa-diacilglicerol-acil-transfer asa 1 (dgat1).
MD4215C1 (ro) Inhibitor al leucemiei mieloide umane în bază de N-(4-(5-(piridin-2-il)-4,5-dihidro-1H-pirazol-3-il)fenil)-2-(piridin-2-ilmetilen)-hidrazincarbotioamidă
PH12017501832A1 (en) Stabilized pharmaceutical composition
WO2014038881A3 (ko) 피리돈 유도체를 포함하는 단백질 키나제 억제제
MX2016005869A (es) Inhibidor de beta-lactamasa cristalina.